{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:49:34Z","timestamp":1787028574155,"version":"build-2736575974"},"reference-count":158,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T00:00:00Z","timestamp":1761436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["23-13-00344"],"award-info":[{"award-number":["23-13-00344"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The problem of acquiring chemoresistance by tumor cells is a growing concern for researchers as the effectiveness of diagnosis and treatment of primary tumors increases. To study the mechanisms of resistance, as well as to evaluate the effectiveness of new drugs, it is necessary to use adequate cell models. The review presents modern methods for obtaining chemoresistant cell lines used by researchers in such studies. It examines the most common cytostatics and targeted drugs, such as cisplatin, oxaliplatin, paclitaxel, doxorubicin, 5-fluorouracil, gemcitabine, gefitinib, bortezomib, erlotinib, and the monoclonal antibody cetuximab. Particular attention is paid to cell mechanisms activated due to drug resistance development and to methods of cell cultivation in the presence of drugs. The presented information provides an opportunity to discuss trends in the creation of chemoresistant cell lines for further research on resistance mechanisms and the development of new therapeutic strategies.<\/jats:p>","DOI":"10.3390\/ijms262110400","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:51:42Z","timestamp":1761526302000},"page":"10400","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Managed Acquisition of Chemoresistance as an Informative Tool for Tumor Research"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1271-0328","authenticated-orcid":false,"given":"Tatyana A.","family":"Grigoreva","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Pharmacology, St. Petersburg State Institute of Technology, St. Petersburg 190013, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0181-4968","authenticated-orcid":false,"given":"Daria N.","family":"Kindt","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Pharmacology, St. Petersburg State Institute of Technology, St. Petersburg 190013, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6280-1979","authenticated-orcid":false,"given":"Aleksandra V.","family":"Sagaidak","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Pharmacology, St. Petersburg State Institute of Technology, St. Petersburg 190013, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0290-1668","authenticated-orcid":false,"given":"Angelina A.","family":"Romanova","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Pharmacology, St. Petersburg State Institute of Technology, St. Petersburg 190013, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7723-4962","authenticated-orcid":false,"given":"Vyacheslav G.","family":"Tribulovich","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Pharmacology, St. Petersburg State Institute of Technology, St. Petersburg 190013, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,26]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Bukowski, K., Kciuk, M., and Kontek, R. (2020). Mechanisms of multidrug resistance in cancer chemotherapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093233"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jare.2014.11.008","article-title":"P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: A review","volume":"6","author":"Abdallah","year":"2015","journal-title":"J. Adv. Res."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Marques, A.V.L., Ruginsk, B.E., Prado, L.O., de Lima, D.E., Daniel, I.W., Moure, V.R., and Valdameri, G. (2025). The association of ABC proteins with multidrug resistance in cancer. Biochim. Biophys. Acta (BBA)-Mol. Cell Res., 1872.","DOI":"10.1016\/j.bbamcr.2024.119878"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Grigoreva, T., Sagaidak, A., Novikova, D., and Tribulovich, V. (2024). New Insights into Chemoresistance Mediated by Mdm2 Inhibitors: The Benefits of Targeted Therapy over Common Cytostatics. Biomedicines, 12.","DOI":"10.3390\/biomedicines12030547"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.biocel.2004.11.004","article-title":"Breast cancer resistance protein (BCRP\/ABCG2)","volume":"37","author":"Staud","year":"2005","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"175327","DOI":"10.1016\/j.ejphar.2022.175327","article-title":"Implication of ABC transporters in non-proliferative diseases","volume":"935","author":"Grigoreva","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Emran, T.B., Shahriar, A., Mahmud, A.R., Rahman, T., Abir, M.H., Siddiquee, M.F., Ahmed, H., Rahman, N., Nainu, F., and Wahyudin, E. (2022). Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.891652"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Habanjar, O., Diab-Assaf, M., Caldefie-Chezet, F., and Delort, L. (2021). 3D Cell Culture Systems: Tumor Application, Advantages, and Disadvantages. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222212200"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ddmod.2011.06.003","article-title":"Organotypic spheroid cultures to study tumor\u2013stroma interaction during cancer development","volume":"8","author":"Dolznig","year":"2011","journal-title":"Drug Discov. Today Dis. Models"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1039\/D0LC01216E","article-title":"An in vitro vascularized micro-tumor model of human colorectal cancer recapitulates in vivo responses to standard-of-care therapy","volume":"21","author":"Hachey","year":"2021","journal-title":"Lab Chip"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Sobrino, A., Phan, D.T., Datta, R., Wang, X., Hachey, S.J., Romero-L\u00f3pez, M., Gratton, E., Lee, A.P., George, S.C., and Hughes, C.C. (2016). 3D microtumors in vitro supported by perfused vascular networks. Sci. Rep., 6.","DOI":"10.1038\/srep31589"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1146\/annurev-bioeng-090120-094330","article-title":"Engineering Vascularized Organoid-on-a-Chip Models","volume":"23","author":"Shirure","year":"2021","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/adt.2015.670","article-title":"Drug Discovery Approaches Utilizing Three-Dimensional Cell Culture","volume":"14","author":"Ryan","year":"2016","journal-title":"Assay Drug Dev. Technol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Grigoreva, T.A., Kindt, D.N., Sagaidak, A.V., Novikova, D.S., and Tribulovich, V.G. (2025). Cellular Systems for Colorectal Stem Cancer Cell Research. Cells, 14.","DOI":"10.3390\/cells14030170"},{"key":"ref_16","first-page":"e68957","article-title":"Development of Drug-resistant Cell Lines for Experimental Procedures","volume":"222","author":"Kadomoto","year":"2025","journal-title":"J. Vis. Exp."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/pros.20581","article-title":"The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines","volume":"67","author":"Takeda","year":"2007","journal-title":"Prostate"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.bbrc.2016.09.128","article-title":"Mechanism of paclitaxel resistance in a human prostate cancer cell line, PC3-PR, and its sensitization by cabazitaxel","volume":"479","author":"Sobue","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cyto.2013.06.313","article-title":"CCR1\/CCL5 interaction promotes invasion of taxane-resistant PC3 prostate cancer cells by increasing secretion of MMPs 2\/9 and by activating ERK and Rac signaling","volume":"64","author":"Kato","year":"2013","journal-title":"Cytokine"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.3892\/mmr.2015.3468","article-title":"Paclitaxel resistance in MCF-7\/PTX cells is reversed by paeonol through suppression of the SET\/phosphatidylinositol 3-kinase\/Akt pathway","volume":"12","author":"Zhang","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Aniogo, E.C., George, B.P., and Abrahamse, H. (2022). Characterization of resistant MCF-7 breast cancer cells developed by repeated cycles of photodynamic therapy. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.964141"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Karimifard, S.A., Salehzadeh-Yazdi, A., Taghizadeh-Tabarsi, R., and Akbari-Birgani, S. (2024). Mechanical effects modulate drug resistance in MCF-7-derived organoids: Insights into the wnt\/\u03b2-catenin pathway. Biochem. Biophys. Res. Commun., 695.","DOI":"10.1016\/j.bbrc.2023.149420"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s12276-020-00510-w","article-title":"METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner","volume":"53","author":"Pan","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Wang, H., Vo, T., Hajar, A., Li, S., Chen, X., Parissenti, A.M., Brindley, D.N., and Wang, Z. (2014). Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-37"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ygyno.2010.07.036","article-title":"Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines","volume":"119","author":"Angelucci","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Kim, Y., Yun, H.J., Choi, K.H., Kim, C.W., Lee, J.H., Weicker, R., Kim, S.M., and Park, K.C. (2023). Discovery of New Anti-Cancer Agents against Patient-Derived Sorafenib-Resistant Papillary Thyroid Cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242216413"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1039\/D0DT03566A","article-title":"Cu(I) complexes as new antiproliferative agents against sensitive and doxorubicin resistant colorectal cancer cells: Synthesis, characterization, and mechanisms of action","volume":"50","author":"Sequeira","year":"2021","journal-title":"Dalton Trans."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Maleki Vareki, S., Salim, K.Y., Danter, W.R., and Koropatnick, J. (2018). Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0191766"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nature10762","article-title":"Clonal evolution in cancer","volume":"481","author":"Greaves","year":"2012","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.semcancer.2015.03.001","article-title":"Broad targeting of resistance to apoptosis in cancer","volume":"35","author":"Mohammad","year":"2015","journal-title":"Semin. Cancer Biol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Babaei, G., Aziz, S.G., and Jaghi, N.Z.Z. (2021). EMT, cancer stem cells and autophagy; The three main axes of metastasis. Biomed. Pharmacother., 133.","DOI":"10.1016\/j.biopha.2020.110909"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2005420","DOI":"10.1080\/21688370.2021.2005420","article-title":"Dual role of E-cadherin in cancer cells","volume":"10","author":"Rubtsova","year":"2022","journal-title":"Tissue Barriers"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"108503","DOI":"10.1016\/j.jmgm.2023.108503","article-title":"Computational analysis of drug resistance of taxanes bound to human \u03b2-tubulin mutant (D26E)","volume":"123","author":"Uba","year":"2023","journal-title":"J. Mol. Graph. Model."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: An evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Shehzad, A. (2022). Biomarkers in Cancer Survival and Drug Resistance. Cancer Biomarkers in Diagnosis and Therapeutics, Springer.","DOI":"10.1007\/978-981-16-5759-7"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Barathan, M., Zulpa, A.K., Ng, S.L., Lokanathan, Y., Ng, M.H., and Law, J.X. (2024). Innovative Strategies to Combat 5-Fluorouracil Resistance in Colorectal Cancer: The Role of Phytochemicals and Extracellular Vesicles. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25137470"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Sethy, C., and Kundu, C.N. (2021). 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implication of DNA repair inhibition. Biomed. Pharmacother., 137.","DOI":"10.1016\/j.biopha.2021.111285"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Liao, J., Qin, Q.H., Lv, F.Y., Huang, Z., Lian, B., Wei, C.Y., Mo, Q.G., and Tan, Q.X. (2023). IKK\u03b1 inhibition re-sensitizes acquired adriamycin-resistant triple negative breast cancer cells to chemotherapy-induced apoptosis. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-33358-x"},{"key":"ref_39","first-page":"915","article-title":"Establishment and characterization of multidrug-resistant gastric cancer cell lines","volume":"30","author":"Zhang","year":"2010","journal-title":"Anticancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41420-021-00590-1","article-title":"Compound 968 reverses adriamycin resistance in breast cancer MCF-7ADR cells via inhibiting P-glycoprotein function independently of glutaminase","volume":"7","author":"Yang","year":"2021","journal-title":"Cell Death Discov."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Oh, Y., Lee, J.S., Lee, J.S., Park, J.H., Kim, H.S., and Yoon, S. (2022). JAK2 Inhibitor, Fedratinib, Inhibits P-gp Activity and Co-Treatment Induces Cytotoxicity in Antimitotic Drug-Treated P-gp Overexpressing Resistant KBV20C Cancer Cells. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23094597"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1021\/acsmedchemlett.2c00196","article-title":"ATP Mimetic Attack on the Nucleotide-Binding Domain to Overcome ABC Transporter Mediated Chemoresistance","volume":"13","author":"Grigoreva","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Grigoreva, T., Romanova, A., Sagaidak, A., Vorona, S., Novikova, D., and Tribulovich, V. (2020). Mdm2 inhibitors as a platform for the design of P-glycoprotein inhibitors. Bioorg. Med. Chem. Lett., 30.","DOI":"10.1016\/j.bmcl.2020.127424"},{"key":"ref_44","first-page":"48","article-title":"Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer","volume":"23","author":"Lu","year":"2021","journal-title":"Mol. Med. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s12195-024-00798-y","article-title":"Three-Dimensional Tumor Models to Study Cancer Stemness-Mediated Drug Resistance","volume":"17","author":"Lamichhane","year":"2024","journal-title":"Cell. Mol. Bioeng."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"788","DOI":"10.20517\/cdr.2023.93","article-title":"Emerging roles of 3D-culture systems in tackling tumor drug resistance","volume":"6","author":"Nikdouz","year":"2023","journal-title":"Cancer Drug Resist."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jss.2007.03.016","article-title":"Characterization of primary breast carcinomas grown in three-dimensional cultures","volume":"142","author":"Becker","year":"2007","journal-title":"J. Surg. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.drudis.2012.10.003","article-title":"Three-dimensional cell culture: The missing link in drug discovery","volume":"18","author":"Breslin","year":"2013","journal-title":"Drug Discov. Today."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Amaral, R.L.F., Miranda, M., Marcato, P.D., and Swiech, K. (2017). Comparative analysis of 3D bladder tumor spheroids obtained by forced floating and hanging drop methods for drug screening. Front. Physiol., 8.","DOI":"10.3389\/fphys.2017.00605"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"9064","DOI":"10.1073\/pnas.89.19.9064","article-title":"Interaction with Basement Membrane Serves to Rapidly Distinguish Growth and Differentiation Pattern of Normal and Malignant Human Breast Epithelial Cells","volume":"89","author":"Petersen","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Ramzy, G.M., Koessler, T., Ducrey, E., McKee, T., Ris, F., Buchs, N., Rubbia-Brandt, L., Dietrich, P.Y., and Nowak-Sliwinska, P. (2020). Patient-derived in vitro models for drug discovery in colorectal carcinoma. Cancers, 12.","DOI":"10.3390\/cancers12061423"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1101\/gad.1061803","article-title":"In vitro propagation and transcriptional profiling of human mammary stem\/progenitor cells","volume":"17","author":"Dontu","year":"2003","journal-title":"Genes Dev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"5506","DOI":"10.1158\/0008-5472.CAN-05-0626","article-title":"Isolation and in vitro propagation of tumorigenic breast cancer cells with stem\/progenitor cell properties","volume":"65","author":"Ponti","year":"2005","journal-title":"Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.biotechadv.2016.11.002","article-title":"3D tumor spheroids: An overview on the tools and techniques used for their analysis","volume":"34","author":"Costa","year":"2016","journal-title":"Biotechnol. Adv."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nrclinonc.2011.34","article-title":"High drug attrition rates-where are we going wrong?","volume":"8","author":"Hutchinson","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Bahmad, H.F., Cheaito, K., Chalhoub, R.M., Hadadeh, O., Monzer, A., Ballout, F., El-Hajj, A., Mukherji, D., Liu, Y.N., and Daoud, G. (2018). Sphere-Formation Assay: Three-Dimensional in vitro Culturing of Prostate Cancer Stem\/Progenitor Sphere-Forming Cells. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00347"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Costa, E.C., de Melo-Diogo, D., Moreira, A.F., Carvalho, M.P., and Correia, I.J. (2018). Spheroids formation on non-adhesive surfaces by liquid overlay technique: Considerations and practical approaches. Biotechnol. J., 13.","DOI":"10.1002\/biot.201700417"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1517\/14712598.2012.707181","article-title":"Advances in the formation, use and understanding of multi-cellular spheroids","volume":"12","author":"Achilli","year":"2012","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1634\/stemcells.2006-0523","article-title":"Rotary suspension culture enhances the efficiency, yield, and homogeneity of embryoid body differentiation","volume":"25","author":"Carpenedo","year":"2007","journal-title":"Stem Cells"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Smart, C.E., Morrison, B.J., Saunus, J.M., Vargas, A.C., Keith, P., Reid, L., Wockner, L., Amiri, M.A., Sarkar, D., and Simpson, P.T. (2013). In Vitro analysis of breast cancer cell line tumourspheres and primary human breast epithelia mammospheres demonstrates inter- and intrasphere heterogeneity. PLoS ONE, 8.","DOI":"10.1371\/annotation\/1ba8c49a-f6cb-4565-8a36-7d7c429ea670"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1126\/science.1253533","article-title":"Cancer Therapy. Ex Vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility","volume":"345","author":"Yu","year":"2014","journal-title":"Science"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jhep.2019.06.030","article-title":"Generation of expandable human pluripotent stem cell-derived hepatocyte-like liver organoids","volume":"71","author":"Mun","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nprot.2016.006","article-title":"Organoid culture systems for prostate epithelial and cancer tissue","volume":"11","author":"Drost","year":"2016","journal-title":"Nat. Protoc."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/nprot.2016.097","article-title":"Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation","volume":"11","author":"Broutier","year":"2016","journal-title":"Nat. Protoc."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"G257","DOI":"10.1152\/ajpgi.00410.2016","article-title":"CRISPR\/Cas 9 genome editing and its applications in organoids","volume":"312","author":"Driehuis","year":"2017","journal-title":"Am. J. Physiol.-Gastrointest. Liver Physiol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Langhans, S.A. (2018). Three-Dimensional in Vitro Cell Culture Models in Drug Discovery and Drug Repositioning. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.00006"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15761\/CDP.1000110","article-title":"Patient-Derived-Tumor-Xenograft: Modeling cancer for basic and translational cancer research","volume":"1","author":"Fiore","year":"2017","journal-title":"Clin. Diagn. Pathol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"9663","DOI":"10.1007\/s11033-023-08809-3","article-title":"Cancer treatment therapies: Traditional to modern approaches to combat cancers","volume":"50","author":"Kaur","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"ref_69","first-page":"3855","article-title":"Tumor microenvironment: Recent advances in various cancer treatments","volume":"22","author":"Wang","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"znae021","DOI":"10.1093\/bjs\/znae021","article-title":"Survival and safety after neoadjuvant chemotherapy or upfront surgery for locally advanced colon cancer: Meta-analysis","volume":"111","author":"Aliseda","year":"2024","journal-title":"Br. J. Surg."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1136\/ijgc-2022-003920","article-title":"Impact of consolidation chemotherapy after delayed complete surgery in advanced epithelial ovarian cancer: A propensity score analysis","volume":"33","author":"Godfroy","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e1089","DOI":"10.1097\/SLA.0000000000005481","article-title":"Oncological Outcome of Conversion Surgery After Preoperative Chemotherapy for Metastatic Pancreatic Cancer","volume":"277","author":"Hank","year":"2023","journal-title":"Ann. Surg."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Tilsed, C.M., Fisher, S.A., Nowak, A.K., Lake, R.A., and Lesterhuis, W.J. (2022). Cancer chemotherapy: Insights into cellular and tumor microenvironmental mechanisms of action. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.960317"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e1920833","DOI":"10.1001\/jamanetworkopen.2019.20833","article-title":"Assessment of clinical activity of PD-1 checkpoint inhibitor combination therapies reported in clinical trials","volume":"3","author":"Schmidt","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"Hulshof","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/ijc.33203","article-title":"Survival impact of adjuvant chemotherapy in patients with stage IIA colon cancer: Analysis of the National Cancer Database","volume":"148","author":"Achilli","year":"2021","journal-title":"Int. J. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.2174\/0929867323666161214114948","article-title":"Combination platinum-based and DNA damage response-targeting cancer therapy: Evolution and future directions","volume":"24","author":"Basourakos","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/277665a0","article-title":"Promotion of microtubule assembly in vitro by taxol","volume":"277","author":"Schiff","year":"1979","journal-title":"Nature"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1126\/science.6093249","article-title":"Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II","volume":"226","author":"Tewey","year":"1984","journal-title":"Science"},{"key":"ref_80","unstructured":"DeVita, V.T., Lawrence, T.S., and Rosenberg, S.A. (2008). Devita, Hellman, and Rosenberg\u2019s Cancer: Principles & Practice of Oncology, Lippincott Williams & Wilkins (Wolters Kluwer Health). [8th ed.]."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","article-title":"Molecular targeted therapy: Treating cancer with specificity","volume":"834","author":"Lee","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/s12276-022-00864-3","article-title":"Molecular targeted therapy for anticancer treatment","volume":"54","author":"Min","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Homayouni","year":"2017","journal-title":"Oncotarget"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2129884","DOI":"10.1080\/08941939.2022.2129884","article-title":"Pancreatic Cancer: A Review of Current Treatment and Novel Therapies","volume":"36","author":"Kolbeinsson","year":"2023","journal-title":"J. Investig. Surg."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/ijc.20985","article-title":"Establishment of a human non-small cell lung cancer cell line resistant to gefitinib","volume":"116","author":"Koizumi","year":"2005","journal-title":"Int. J. Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1158\/1078-0432.CCR-08-2068","article-title":"Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells","volume":"15","author":"Benavente","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.3892\/mmr.2014.3058","article-title":"Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975\/gefinitib-resistant with epidermal growth factor receptor T790M mutation","volume":"11","author":"Zhao","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.1007\/s11033-020-05464-w","article-title":"Plumbagin promotes mitochondrial mediated apoptosis in gefitinib sensitive and resistant A549 lung cancer cell line through enhancing reactive oxygen species generation","volume":"47","author":"Panda","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Grigoreva, T., Sagaidak, A., Romanova, A., Novikova, D., Garabadzhiu, A., and Tribulovich, V. (2021). Establishment of drug-resistant cell lines under the treatment with chemicals acting through different mechanisms. Chem. Biol. Interact., 344.","DOI":"10.1016\/j.cbi.2021.109510"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"6443","DOI":"10.21873\/anticanres.13858","article-title":"Establishment of Drug-resistant Cell Lines as a Model in Experimental Oncology: A Review","volume":"39","author":"Amaral","year":"2019","journal-title":"Anticancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3892\/or.2014.3314","article-title":"Establishment and characterization of a cisplatin-resistant human osteosarcoma cell line","volume":"32","author":"Han","year":"2014","journal-title":"Oncol. Rep."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.3892\/mmr.2015.3768","article-title":"Establishment and characterization of triple drug resistant head and neck squamous cell carcinoma cell lines","volume":"12","author":"Govindan","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.3748\/wjg.v16.i18.2291","article-title":"Establishment of a human hepatoma multidrug resistant cell line in vitro","volume":"16","author":"Zhou","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s002800050632","article-title":"Establishment of a cisplatin-resistant gastric carcinoma cell line OCUM-2M\/DDP","volume":"40","author":"Nitta","year":"1997","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Noordhuis, P., Laan, A.C., van de Born, K., Honeywell, R.J., and Peters, G.J. (2019). Coexisting Molecular Determinants of Acquired Oxaliplatin Resistance in Human Colorectal and Ovarian Cancer Cell Lines. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20153619"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/s41417-023-00595-1","article-title":"LncRNA-NEF suppressed oxaliplatin resistance and epithelial-mesenchymal transition in colorectal cancer through epigenetically inactivating MEK\/ERK signaling","volume":"30","author":"Shi","year":"2023","journal-title":"Cancer Gene Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e2301088","DOI":"10.1002\/advs.202301088","article-title":"Inhibition of CDK1 Overcomes Oxaliplatin Resistance by Regulating ACSL4-mediated Ferroptosis in Colorectal Cancer","volume":"10","author":"Zeng","year":"2023","journal-title":"Adv. Sci."},{"key":"ref_98","first-page":"6135","article-title":"Establishment of paclitaxel-resistant breast cancer cell line and nude mice models, and underlying multidrug resistance mechanisms in vitro and in vivo. Asian Pac","volume":"14","author":"Chen","year":"2013","journal-title":"J. Cancer Prev."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.taap.2016.09.020","article-title":"Characterization of acquired paclitaxel resistance of breast cancer cells and involvement of ABC transporters","volume":"310","author":"Daniel","year":"2016","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_100","first-page":"BR184","article-title":"The establishment and characterization of adriamycin-resistant cell lines derived from Saos-2","volume":"16","author":"Niu","year":"2010","journal-title":"Med. Sci. Monit."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s002400050143","article-title":"Establishment and characterization of renal cell carcinoma cell lines with multidrug resistance","volume":"28","author":"Yu","year":"2000","journal-title":"Urol. Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/00001813-200110000-00009","article-title":"Establishment and characterization of adriamycin-resistant human colorectal adenocarcinoma HCT-15 cell lines with multidrug resistance","volume":"12","author":"Watanabe","year":"2001","journal-title":"Anticancer Drugs"},{"key":"ref_103","first-page":"191","article-title":"Establishment of an adriamycin-resistant subline of human small cell lung cancer showing multifactorial mechanisms of resistance","volume":"47","author":"Kiura","year":"1993","journal-title":"Acta Med. Okayama"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1007\/s13277-014-2959-9","article-title":"Establishment and characterization of a bladder cancer cell line with enhanced doxorubicin resistance by mevalonate pathway activation","volume":"36","author":"Greife","year":"2015","journal-title":"Tumour Biol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1023\/B:BREA.0000021046.29834.12","article-title":"Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure","volume":"85","author":"Guo","year":"2004","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0022-5347(17)36624-7","article-title":"Establishment and characterization of doxorubicin-resistant human bladder cancer cell line, KK47\/ADM","volume":"148","author":"Kimiya","year":"1992","journal-title":"J. Urol."},{"key":"ref_107","first-page":"859","article-title":"Establishment of new multidrug-resistant human osteosarcoma cell lines","volume":"7","author":"Oda","year":"2000","journal-title":"Oncol. Rep."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.3892\/ijo.2014.2270","article-title":"Establishment of 5-fluorouracil-resistant oral squamous cell carcinoma cell lines with epithelial to mesenchymal transition changes","volume":"44","author":"Harada","year":"2014","journal-title":"Int. J. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.3892\/ijo.2013.2135","article-title":"Establishment of a 5-fluorouracil-resistant triple-negative breast cancer cell line","volume":"43","author":"Takahashi","year":"2013","journal-title":"Int. J. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3892\/ijo.2015.3019","article-title":"Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness","volume":"47","author":"Wattanawongdon","year":"2015","journal-title":"Int. J. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Chiu, C.H., Lin, Y.J., Ramesh, S., Kuo, W.W., Chen, M.C., Kuo, C.H., Li, C.C., Wang, T.F., Lin, Y.M., and Liao, P.H. (2023). Gemcitabine resistance in non-small cell lung cancer is mediated through activation of the PI3K\/AKT\/NF-\u03baB pathway and suppression of ERK signaling by reactive oxygen species. J. Biochem. Mol. Toxicol., 37.","DOI":"10.1002\/jbt.23497"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3892\/or.2014.3599","article-title":"Establishment of human pancreatic cancer gemcitabine-resistant cell line with ribonucleotide reductase overexpression","volume":"33","author":"Wang","year":"2015","journal-title":"Oncol. Rep."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1080\/10428194.2016.1266621","article-title":"Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry","volume":"58","author":"Baughn","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5483\/BMBRep.2014.47.5.134","article-title":"Establishment and characterization of bortezomib-resistant U266 cell line: Constitutive activation of NF-\u03baB-mediated cell signals and\/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis","volume":"47","author":"Park","year":"2014","journal-title":"BMB Rep."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Downey-Kopyscinski, S.L., Srinivasa, S., and Kisselev, A.F. (2022). A clinically relevant pulse treatment generates a bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclax. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-17239-3"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Hu, C., Zhou, A., Hu, X., Xiang, Y., Huang, M., Huang, J., Yang, D., and Tang, Y. (2022). LMNA reduced acquired resistance to erlotinib in NSCLC by reversing the epithelial-mesenchymal transition via the FGFR\/MAPK\/c-fos signaling pathway. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232113237"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.7150\/thno.23177","article-title":"Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase","volume":"8","author":"Dong","year":"2018","journal-title":"Theranostics"},{"key":"ref_118","first-page":"1921","article-title":"Establishment and characterization of cetuximab resistant head and neck squamous cell carcinoma cell lines: Focus on the contribution of the AP-1 transcription factor","volume":"5","author":"Boeckx","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Tsou, S.H., Chen, T.M., Hsiao, H.T., and Chen, Y.H. (2015). A critical dose of doxorubicin is required to alter the gene expression profiles in MCF-7 cells acquiring multidrug resistance. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0116747"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1186\/s12964-024-01788-3","article-title":"Characterization of two melanoma cell lines resistant to BRAF\/MEK inhibitors (vemurafenib and cobimetinib)","volume":"22","author":"Kot","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"ref_121","first-page":"54714","article-title":"Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models","volume":"118","author":"Sciarrillo","year":"2016","journal-title":"J. Vis. Exp."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1054\/bjoc.2000.1311","article-title":"Modulation of paclitaxel resistance by annexin IV in human cancer cell lines","volume":"83","author":"Han","year":"2000","journal-title":"Br. J. Cancer"},{"key":"ref_123","first-page":"65","article-title":"Establishment and biological analysis of the EC109\/CDDP multidrug-resistant esophageal squamous cell carcinoma cell line","volume":"22","author":"Wen","year":"2009","journal-title":"Oncol. Rep."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s00345-018-2501-6","article-title":"Paclitaxel resistance and the role of miRNAs in prostate cancer cell lines","volume":"37","author":"Samli","year":"2019","journal-title":"World J. Urol."},{"key":"ref_125","first-page":"619","article-title":"Autophagy inhibition re-sensitizes pulse stimulation-selected paclitaxel-resistant triple negative breast cancer cells to chemotherapy-induced apoptosis. Breast Cancer Res","volume":"149","author":"Wen","year":"2015","journal-title":"Treat."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Krzywik, J., Aminpour, M., Maj, E., Mozga, W., Wietrzyk, J., Tuszy\u0144ski, J.A., and Huczy\u0144ski, A. (2020). New Series of Double-Modified Colchicine Derivatives: Synthesis, Cytotoxic Effect and Molecular Docking. Molecules, 25.","DOI":"10.3390\/molecules25153540"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Lahmar, A., Mathey, A., Aires, V., Elgueder, D., Vejux, A., Khlifi, R., Sioud, F., Chekir-Ghedira, L., and Delmas, D. (2021). Essential Oils, Pituranthos chloranthus and Teucrium ramosissimum, Chemosensitize Resistant Human Uterine Sarcoma MES-SA\/Dx5 Cells to Doxorubicin by Inducing Apoptosis and Targeting P-Glycoprotein. Nutrients, 13.","DOI":"10.3390\/nu13051719"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.bbagen.2006.12.002","article-title":"Biophysical characterization of MDR breast cancer cell lines reveals the cytoplasm is critical in determining drug sensitivity","volume":"1770","author":"Coley","year":"2007","journal-title":"Biochim. Biophys. Acta (BBA)-Gen. Subj."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"McDermott, M., Eustace, A.J., Busschots, S., Breen, L., Crown, J., Clynes, M., O\u2019Donovan, N., and Stordal, B. (2014). In vitro Devel-opment of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies. Front. Oncol., 4.","DOI":"10.3389\/fonc.2014.00040"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Packeiser, E.M., Engels, L., Nolte, I., Goericke-Pesch, S., and Murua Escobar, H. (2023). MDR1 Inhibition Reverses Doxorubi-cin-Resistance in Six Doxorubicin-Resistant Canine Prostate and Bladder Cancer Cell Lines. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24098136"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1134\/S1990519X22060037","article-title":"Establishment and Characterization of Human Colon-Cancer Cells Resistant to Cisplatin","volume":"16","author":"Morshneva","year":"2022","journal-title":"Cell Tissue Biol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s00280-002-0452-4","article-title":"Establishment of cisplatin-resistant variants of human neuroblastoma cell lines, TGW and GOTO, and their drug cross-resistance profiles","volume":"49","author":"Iwasaki","year":"2002","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000320744","article-title":"Establishment of cis-platin-resistant ovarian yolk sac tumor cells and investigation of the mechanism of cisplatin resistance using this cell line","volume":"71","author":"Shibata","year":"2011","journal-title":"Gynecol. Obstet. Investig."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/CAD.0b013e3280200428","article-title":"Establishment and gene analysis of an oxaliplatin-resistant colon cancer cell line THC8307\/L-OHP","volume":"18","author":"Tang","year":"2007","journal-title":"Anticancer Drugs"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1177\/147323001003800424","article-title":"Establishment of a paclitaxel resistant human breast cancer cell strain (MCF-7\/Taxol) and intracellular paclitaxel binding protein analysis","volume":"38","author":"Zuo","year":"2010","journal-title":"J. Int. Med. Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1007\/s11033-010-9975-7","article-title":"Establishment and identification of the human multi-drug-resistant cholangiocarcinoma cell line QBC939\/ADM","volume":"38","author":"Liu","year":"2011","journal-title":"Mol. Biol. Rep."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"\u015aroda-Pomianek, K., Michalak, K., Palko-\u0141abuz, A., Uryga, A., \u015awi\u0105tek, P., Majkowski, M., and Weso\u0142owska, O. (2019). The Combined Use of Phenothiazines and Statins Strongly Affects Doxorubicin-Resistance, Apoptosis, and Cox-2 Activity in Colon Cancer Cells. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20040955"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1002\/mc.22996","article-title":"Doxorubicin induces prostate cancer drug resistance by upregulation of ABCG4 through GSH depletion and CREB activation: Relevance of statins in chemosensitization","volume":"58","author":"Mallappa","year":"2019","journal-title":"Mol. Carcinog."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3892\/ijo.2011.1300","article-title":"Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines","volume":"40","author":"Uchibori","year":"2012","journal-title":"Int. J. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Kim, M.J., Kim, H.S., Kang, H.W., Lee, D.E., Hong, W.C., Kim, J.H., Kim, M., Cheong, J.H., Kim, H.J., and Park, J.S. (2023). SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in Pancreatic Cancer. Cells, 12.","DOI":"10.20944\/preprints202309.0814.v1"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s13046-023-02814-x","article-title":"Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP\/PERK\/eIF2\u03b1-axis-mediated endoplasmic reticulum stress","volume":"42","author":"She","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.21037\/jtd.2019.11.25","article-title":"Identification of potential microRNAs and their targets in promoting gefitinib resistance by integrative network analysis","volume":"11","author":"Zheng","year":"2019","journal-title":"J. Thorac. Dis."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Fan, D., Yang, Y., and Zhang, W. (2022). A novel circ_MACF1\/miR-942-5p\/TGFBR2 axis regulates the functional behaviors and drug sensitivity in gefitinib-resistant non-small cell lung cancer cells. BMC Pulm. Med., 22.","DOI":"10.1186\/s12890-021-01731-z"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1158\/0008-5472.CAN-21-4140","article-title":"Inhibition of EGFR overcomes acquired lenvatinib resistance driven by STAT3-ABCB1 signaling in hepatocellular carcinoma","volume":"82","author":"Hu","year":"2022","journal-title":"Cancer Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00018-018-2954-1","article-title":"Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells","volume":"76","author":"Witucka","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1016\/S0021-9258(17)35746-0","article-title":"Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase","volume":"261","author":"Davies","year":"1986","journal-title":"J. Biol. Chem."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"e37790","DOI":"10.1097\/MD.0000000000037790","article-title":"A comprehensive exploration of twist1 to identify a biomarker for tumor immunity and prognosis in pan-cancer","volume":"103","author":"Wang","year":"2024","journal-title":"Medicine"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"v7","DOI":"10.1093\/annonc\/mdj941","article-title":"Cellular pharmacology of gemcitabine","volume":"17","author":"Mini","year":"2006","journal-title":"Ann. Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Uribe, M.L., Marrocco, I., and Yarden, Y. (2021). EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. Cancers, 13.","DOI":"10.3390\/cancers13112748"},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Ram\u00edrez Moreno, M., and Bulgakova, N.A. (2022). The Cross-Talk Between EGFR and E-Cadherin. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.828673"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/s41375-020-0989-4","article-title":"Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma","volume":"35","author":"Allmeroth","year":"2021","journal-title":"Leukemia"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"10317","DOI":"10.1021\/jm300434z","article-title":"Molecular mechanisms of acquired proteasome inhibitor resistance","volume":"55","author":"Kale","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/leu.2010.137","article-title":"Bortezomib-resistant myeloma cell lines: A role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress","volume":"24","author":"Ri","year":"2010","journal-title":"Leukemia"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s41589-019-0291-9","article-title":"Mitochondrial metabolism promotes adaptation to proteotoxic stress","volume":"15","author":"Tsvetkov","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"101042","DOI":"10.1016\/j.drup.2023.101042","article-title":"Inhibition of NF-\u03baB signaling unveils novel strategies to overcome drug resistance in cancers","volume":"73","author":"Li","year":"2024","journal-title":"Drug Resist. Updates"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13048-016-0278-z","article-title":"Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines","volume":"9","author":"Januchowski","year":"2016","journal-title":"J. Ovarian Res."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1038\/s41388-020-01492-9","article-title":"Molecular biological analysis of 5-FU-resistant gastric cancer organoids; KHDRBS3 contributes to the attainment of features of cancer stem cell","volume":"39","author":"Ukai","year":"2020","journal-title":"Oncogene"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nprot.2008.226","article-title":"Spheroid-based drug screen: Considerations and practical approach","volume":"4","author":"Friedrich","year":"2009","journal-title":"Nat. Protoc."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/21\/10400\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:58:51Z","timestamp":1761526731000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/21\/10400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,26]]},"references-count":158,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["ijms262110400"],"URL":"https:\/\/doi.org\/10.3390\/ijms262110400","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,26]]}}}